Molecular Partners Other Current Assets Over Time
| MOLN Stock | USD 5.62 0.33 6.24% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Molecular Partners Performance and Molecular Partners Correlation. Molecular |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.12) | Revenue Per Share 0.182 | Quarterly Revenue Growth (0.73) | Return On Assets (0.21) | Return On Equity (0.37) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Current Assets Analysis
Compare Molecular Partners and related stocks such as Mineralys Therapeutics,, AN2 Therapeutics, and Pharvaris BV Other Current Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MLYS | 57 K | 57 K | 57 K | 57 K | 57 K | 57 K | 57 K | 57 K | 57 K | 57 K | 57 K | 460 K | 2.7 M | 12.5 M | 13.2 M |
| ANTX | 102 K | 102 K | 102 K | 102 K | 102 K | 102 K | 102 K | 102 K | 102 K | 102 K | 164 K | 1.6 M | 2.6 M | 3.2 M | 1.7 M |
| PHVS | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 22.6 K | 47.5 K | 1.8 M | 1.5 M | 4.6 M | 5.6 M | 5.9 M |
| PEPG | 53 K | 53 K | 53 K | 53 K | 53 K | 53 K | 53 K | 53 K | 53 K | 53 K | 134 K | 2.3 M | 4.3 M | 2.3 M | 2 M |
| MNOV | 108.4 K | 614.5 K | 411.6 K | 1.7 M | 463.5 K | 649.5 K | 585.8 K | 336.6 K | 444.9 K | 511.9 K | 680.2 K | 578 K | 499.4 K | 174.9 K | 166.2 K |
| ANEB | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 1.7 M | 1 M | 422.7 K | 413.8 K | 565.7 K |
| CSBR | 20 K | 205 K | 358 K | 383 K | 346 K | 443 K | 300 K | 287 K | 308 K | 385 K | 957 K | 2.3 M | 1.3 M | 1.5 M | 1.6 M |
| RZLT | 95.5 K | 95.5 K | 95.5 K | 83.4 K | 320.3 K | 430.1 K | 442 K | 361.9 K | 571 K | 563 K | 1.9 M | 1.7 M | 3 M | 1.8 M | 1 M |
| HCWB | 236.3 K | 236.3 K | 236.3 K | 236.3 K | 236.3 K | 236.3 K | 236.3 K | 236.3 K | 236.3 K | 236.3 K | 1.2 M | 1.4 M | 1.6 M | 1.3 M | 1.3 M |
| PMVP | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 332 K | 607 K | 6.7 M | 4.1 M | 6 M | 4.4 M | 4 M |
| EWTX | 390 K | 390 K | 390 K | 390 K | 390 K | 390 K | 390 K | 390 K | 390 K | 390 K | 551 K | 6 M | 10.1 M | 8.6 M | 5.6 M |
| RLYB | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 2.1 M | 10.7 M | 20 M | 7.7 M | 9.2 M |
| OPT | 265.4 K | 76.8 K | 1.8 M | 2.3 M | 2.5 M | 1.3 M | 2.2 M | 9 M | 208.3 K | 329.5 K | 14.7 K | 8.7 M | 2.6 M | 3.9 M | 4.1 M |
| GLUE | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 514 K | 1.8 M | 5.2 M | 5.4 M | 3.3 M | 3.6 M |
| TRDA | 593 K | 593 K | 593 K | 593 K | 593 K | 593 K | 593 K | 593 K | 593 K | 593 K | 904 K | 7.6 M | 21.2 M | 27.7 M | 29.1 M |
| VIGL | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 6.1 M | 11.2 M | 2.5 M | 2.4 M |
Molecular Partners and related stocks such as Mineralys Therapeutics,, AN2 Therapeutics, and Pharvaris BV Other Current Assets description
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.My Equities
My Current Equities and Potential Positions
| Molecular Partners AG | MOLN |
| Classification | Health Management |
| Location | Switzerland |
| Exchange | NASDAQ Exchange |
USD 5.62
Check out Molecular Partners Performance and Molecular Partners Correlation. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Molecular Partners technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.